Merck has announced a new agreement with the ADAP Crisis Task Force (ACTF) to expand access to its once-daily HIV treatment, IDVYNSO (doravirine/islatravir), through state AIDS Drug Assistance Programs (ADAPs), which supported more than 250,000 people living with HIV in the U.S. in 2024.
Also read: UAE oncology experts gather to unpack latest global cancer research
Approved by the U.S. Food and Drug Administration (FDA) in April 2026, IDVYNSO is a two-drug, single-tablet regimen for adults with HIV-1 who are virologically suppressed on a stable treatment plan. The collaboration aims to improve access for eligible uninsured and underserved patients while helping address ongoing gaps in HIV care.
“Merck is pleased to have reached this agreement with the ADAP Crisis Task Force to expand access to IDVYNSO for eligible people with HIV,” said Conrod Kelly, U.S. HIV business unit head, Merck. “This agreement reflects our long-standing commitment to working with the ACTF, state ADAPs and the HIV community to strengthen access and help address persistent gaps in care.”
Merck also offers support through its Access Program, providing eligible patients with information on insurance coverage, out-of-pocket costs, and co-pay assistance to improve treatment affordability.
